Under construction – not a live service
Sign in
Not yet taking people in ChinaNo phase

Tests third-generation EGFR drugs after surgery in early lung cancer patients

Observes EGFR-positive early lung cancer patients with high-risk features taking third-generation EGFR drugs.

Key facts

Who runs it
First Affiliated Hospital of Guangxi Medical University
Where
Nanning, ChinaSee the site
Trial code
Registry title
A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.
Status
Not yet recruiting
People taking part
500 people, planned
Started
1 Sept 2026
Expected to end
31 Dec 2032
Type of study
Observational
Treatments tested
  • Third-generation EGFR-TKI
Record updated
7 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stage IA non-small cell lung cancer, an EGFR mutation and high-risk features, who have had or will have surgery and take a third-generation EGFR-TKI afterwards.

Age
18 years or older
Sex
All sexes can join
Disease stage
Stage IA non-small cell lung cancer (8th edition of the AJCC staging system), confirmed under the microscope, with high-risk factors such as poor differentiation, lymphovascular invasion or spread through air spaces
Earlier treatment
No earlier treatment for the cancer that works through the whole body. Surgery already done or planned. Third-generation EGFR-TKI after surgery already given or planned
Biomarker or test result
EGFR mutation positive

Main reasons for not taking part

  • Small cell lung cancer
  • Another cancer that needs treatment
  • Pregnant or breastfeeding women
  • The researchers think the person should not take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age ≥ 18 years old
  • Patients with IA-stage (8th edition of AJCC staging) non-small cell lung cancer (NSCLC) confirmed by histopathology and with high-risk factors
  • EGFR mutation positive
  • No previous systemic anti-tumor treatment
  • Expected or already received surgical treatment
  • Intended to receive or already received third-generation EGFR-TKI adjuvant therapy after surgery

Who cannot take part

  • Small cell lung cancer
  • With other malignant tumors that require treatment
  • Pregnant or lactating women
  • Those who the researchers consider not suitable to participate in this clinical trial

Where in China

  • The First Affiliated Hospital of Guangxi Medical UniversityNanning, ChinaContact: Nuo YangNo longer taking part

About the trial

What the trial wants to find out

This study aims to evaluate the real-world effectiveness and safety of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)-such as osimertinib, aumolertinib, and furmonertinib-as adjuvant therapy for patients with early-stage non-small cell lung cancer (NSCLC) in China.

Read full original descriptionShow less

Approximately 500 eligible patients are planned to be enrolled. All participants must have been diagnosed with Stage IA NSCLC (according to the 8th edition of the AJCC staging system) following surgical resection, harboring EGFR-sensitive mutations, and presenting with high-risk recurrence factors (e.g., poor differentiation, lymphovascular invasion, and spread through air spaces).

This is a non-interventional, real-world study that does not alter physicians' original prescribing habits or clinical management strategies. Patients will receive standard treatment with third-generation EGFR-TKIs according to routine clinical practice (typically for a duration of three years). The research team will periodically collect follow-up data, with a primary focus on postoperative disease-free survival (DFS) and drug safety profiles.

Through this investigation, we seek to determine whether this specific population of high-risk early-stage patients can derive clinical benefit from postoperative targeted therapy. The findings are expected to provide evidence to support the development of future clinical guidelines.

The group in the trial

  • Observational Group

    Third-generation EGFR-TKI adjuvant therapy for Chinese patients with stage IA EGFR-positive NSCLC who have high-risk factors

    Treatment: Third-generation EGFR-TKI

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Non-interventional, Real-World Study of Third-Generation EGFR-TKI Adjuvant Therapy in Chinese EGFR-Positive Stage IA Non-Small Cell Lung Cancer Patients With High-Risk Factors
Plain-language title
Tests third-generation EGFR drugs after surgery in early lung cancer patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
7 July 2026